# TALAPRO-2 (NCT03395197)

> Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03395197
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Pfizer
- Conditions: mCRPC
- Interventions: Talazoparib with enzalutamide; Placebo with enzalutamide
- Enrollment: 1054
- Primary outcome: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Occuring Within the First 66 Days of Dosing - Part 1
- Primary outcome: Number of Participants With All-Causality Clustered Treatment-Emergent Cytopenias by Preferred Term (PT) and Max CTCAE Grade Occuring Within the First 66 Days of Dosing - Part 1
- Primary outcome: Number of Participants With All-Causality TEAEs During the Overall Period of Part 1
- Primary outcome: Number of Participants With Treatment-Related TEAEs During the Overall Period of Part 1
- Primary outcome: Number of Participants With All-Causality Clustered Treatment-Emergent Cytopenias by PT and Max CTCAE Grade Occuring Anytime After Dosing - Part 1
- Primary outcome: Number of Participants With Treatment-Related Clustered Treatment-Emergent Cytopenias by PT and Max CTCAE Grade in >=10% of Participants Occuring Anytime After Dosing - Part 1
- Primary outcome: Blinded Independent Central Review (BICR) Assessed Radiographic Progression-Free Survival (rPFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for All-Comers - Part 2 Cohort 1
- Primary outcome: BICR Assessed rPFS Per RECIST 1.1 in Patients With DDR Deficiencies - Part 2

## Commentary we found

- X threads: 286
- YouTube: 144
- Podcasts: 122
- X videos: 9

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=talapro-2-nct03395197

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03395197", "email": "<work email>"}; the inbox owner confirms by the emailed link.